VTRS240719P12000
- 0.15
- +0.10+200.00%
Viatris Newsroom
Express News | Jefferies Reinstates Buy on Viatris, Announces $15 Price Target
Viatris Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 27.44% Jefferies → $15 Reinstates Buy → Buy 03/28/2024 10.45% Piper Sandler $11 → $13
Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $15
Jefferies analyst Glen Santangelo maintains $Viatris(VTRS.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 49.5% and a
Big Pharma Rally After J&J Earnings
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
BofA Securities Maintains Viatris(VTRS.US) With Sell Rating
BofA Securities analyst Jason Gerberry maintains $Viatris(VTRS.US)$ with a sell rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -0.6% over
Express News | Viatris Inc : BofA Global Research Cuts Price Objective to $11 From $12
Express News | Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan
Express News | Viatris Brings to Completion All Previously Announced Divestitures With the Closing of Its Over-the-Counter Business Divestiture
Viatris Has Closed the Divestiture of Its Over-the-Counter Business to Cooper Consumer Health >VTRS
Viatris Has Closed the Divestiture of Its Over-the-Counter Business to Cooper Consumer Health >VTRS
Express News | Viatris Shares up 1.7% Premarket After US DOJ Informs Co's Mylan No Longer Part of Antitrust Investigation
Express News | Viatris Inc - DOJ Civil Division to Take No Further Action on Mylan
Express News | U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Express News | Viatris Statement Regarding European Commission’s Approval for Proposed Divestiture of Its Over-the-Counter Business to Cooper Consumer Health
EU: Meeting Conditions Would Address Competition Concerns of Merger
EU: Meeting Conditions Would Address Competition Concerns of Merger
Express News | EU Approval Conditional on Cooper Selling Rights and Interests in Infant Laxative Medicine and Earwax Removal Product
Express News | Cooper Consumer Health Gains EU Antitrust Approval to Buy Viatris' European Over-the-Counter Drug Business
Viatris Named to TIME's World's Most Sustainable Companies 2024 List
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most...
Goldman's Top 50 High Sharpe Ratio Stocks
Goldman Sachs analysts rebalanced their “high Sharpe Ratio” basket, which identifies 50 S&P 500 (SP500) stocks with the highest prospective risk-adjusted returns compared to their sector peers.
Viatris(VTRS.US) Director Sells US$3.59 Million in Common Stock
$Viatris(VTRS.US)$ Director Malik Rajiv sold 349.96K shares of common stock on Jun 13, 14, 2024 at an average price of $10.2612 for a total value of $3.59 million.Source: Announcement What is statemen